1441 Canal Street
About AxoSim Technologies
AxoSim is the first organ-on-a-chip company to focus exclusively on the nervous system. AxoSim’s Nerve-On-A-Chip® platform predicts clinical performance from the benchtop, helping pharmaceutical and defense clients develop safer and more effective therapies, drugs, and countermeasures. This platform grows living human nerves in a proprietary 3D environment to provide a more accurate, efficient, and cost-effective alternative to animal testing compared to anything available on the market.
AxoSim’s Nerve-On-A-Chip® platform is the first-ever 3D in vitro model of the nervous system to deliver human-relevant data to predict clinical outcomes prior to human trials. Current platform applications test both safety, with our neurotoxicity model, and efficacy, using AxoSim’s custom disease models to mimic disease states such as MS and ALS.
4 articles with AxoSim Technologies
Publication Confirms AxoSim's Nerve-on-a-Chip® Technology Embodies Key Nervous System Functions Needed to Speed New Drug R&D
First Biomimetic Model to Demonstrate Myelination of Human Nerve Cells with Human Schwann Cells
AxoSim Licenses Revolutionary Mini-Brain Technology from Johns Hopkins University Enabling the Use of Human Data to Speed New Drug Research
AxoSim, Inc. announced an exclusive license from Johns Hopkins University to intellectual property underlying the "Mini-Brain" technology, which uses induced pluripotent stem cells to create functional models of the human brain.